Across TCGA pan-cancer cohorts, AKAP14 Mutation is linked to patient survival in 4 of 34 cancer types, making it a survival-associated AKAP14 data layer compared with 16 for mass-spec protein and 1 for mass-spec protein.

The strongest signal is observed in bladder urothelial carcinoma (BLCA), where higher AKAP14 Mutation is associated with worse disease-free survival. In most high-consensus cancer types, elevated AKAP14 expression acts as an unfavorable survival marker.

BLCA, HNSC, and UCEC are the cancer types where AKAP14 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
BLCA	DFS	Median	All	0.114	0.626	<.001	24	view →
HNSC	OS	Median	All	0.274	0.662	.040	6	view →
UCEC	OS	Median	IV	0.231	0.592	.036	6	view →
LUAD	DFS	Median	All	0.213	0.676	.012	3	view →

Pink = unfavorable, green = favorable. Showing the 4 strongest of 4 lineages.

Exploration

Same gene, other analysis: AKAP14 tumor-vs-normal RNA expression · all AKAP14 data types